DenCe-ctive – Use of autologous Thrombocytes
The therapeutic use of dendritic cells in vaccination
therapy requires prior activation of these immune cells. The invention exploits the ability of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique possibility of autologous activation. Commercial Opportunities Immune therapy using activated dendritic cells is a well established approach used for various therapies including cancer vaccination strategies. An enormous market potential is expected. The invention provides the first method triggering an autologous maturation of dendritic cells into potent antigen presenting cells. Thus, the method constitutes a highly efficacious approach for inducing T-cell responses. The simple and efficient activation strategy is strikingly easy to handle and compatible with established immunotherapy protocols.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Detector for continuously monitoring toxic gases
The material could be made as a thin coating to analyze air quality in industrial or home settings over time. Most systems used to detect toxic gases in industrial or…
On the way for an active agent against hepatitis E
In order to infect an organ, viruses need the help of the host cells. “An effective approach is therefore to identify targets in the host that can be manipulated by…
A second chance for new antibiotic agent
Significant attempts 20 years ago… The study focused on the protein peptide deformylase (PDF). Involved in protein maturation processes in cells, PDF is essential for the survival of bacteria. However,…